Objectives-To analyse whether the intraindividual variability of the bioavailability of oral methotrexate in rheumatoid arthritis (RA) is as high as the interindividual variability and whether the bioavailability testing can be simplified. Methods-Fifteen mg methotrexate was given orally after an overnight fast to 10 patients with RA on two occasions, one week (n =4) or two years (n =6) apart, respectively. Plasma samples were taken at specific time intervals and analysed by fluorescence polarisation immunoassay. The areas under the plasma concentration versus time curves from 0 to x (AUC) were calculated after fitting to a twocompartment extravascular model with lag time. Results-The interindividual variability of the AUCs showed a more than five fold range from 77 to 471 min x pLmol/l. In contrast, the intraindividual differences of AUCs between the two visits ranged from 3 to 100 min x ,umol/l, reflecting a 3-30% change in nine of 10 patients. Close correlations were found between the AUCs and the plasma concentrations with a most pronounced correlation eight hours after methotrexate intake (r = 0 975; p < 0-001). Conclusions-The high interindividual variability of the AUCs was confirmed. Conversely, only a modest intraindividual variability was disclosed. Plasma sample analysis at a single time point four to eight hours after methotrexate application could simplify estimation of the bioavailability.
In view of the interindividual differences in oral pharmacokinetics, the parenteral application would be preferable to assure complete absorption and prolonged exposure to the drug. This would produce a better clinical efficacy,2 47 but lead to more inconveniences and higher costs.
On theoretical grounds, the oral bioavailability could be determined in a given patient before initiation of the methotrexate treatment and an adequate oral dose derived from the pharmacokinetic data. In case the intraindividual variability of the oral bioavailability is low, oral administration would still be justified. The methotrexate dose could be adjusted according to the concomitant drug treatment, renal function and disease activity during the regular follow ups. However, insufficient data are available. We therefore studied 10 fasted patients with RA on two occasions, comparing pharmacokinetics after intake of 15 mg methotrexate in the hope of defining a simplified test of bioavailability.
Patients and methods

PATIENT POPULATION
To study the intraindividual variability of the bioavailability of low dose oral methotrexate, 10 patients (five women, five men) with rheumatoid arthritis (ARA criteria)8 were assessed on two occasions ( We omitted the measurement of methotrexate plasma concentrations after eight hours for practical reasons. In our previous study, plasma concentrations 24 hours after intake were only slightly above the detection limit.' In addition, the calculated AUC 0 to oo was on average (SD) 23-9 (4-2)% smaller, when only plasma concentrations up to eight hours were included compared with up to 24 hours. This inaccuracy was felt negligible in view of the high interindividual variability of approximately 400%.
All results are given as mean (SD). The significance level was set at p = 0-05.
Results
Methotrexate kinetics showed considerable interindividual differences (table 1). The mean (SD) lag time was 9 9 (10.2) minutes (ranging from 0 0 to 27 2) and 13-5 (8&3) minutes (ranging from 5-7 to 25-7) after the first and second administration, respectively. Peak concentrations were reached after 83 (26) minutes (ranging from 45 to 120) and 93 (22) No obvious reason for the exceptionally long half life of 6-2 hours in patient eight on both occasions could be identified; in particular, renal function and quantitative liver function were normal and there was no concomitant drug treatment that was likely to explain this half life.
The area under the plasma concentration versus time curves from 0 to o (AUC) was used as an estimate of the bioavailability. An enormous interindividual variability with a more than five fold range of the AUCs was revealed, despite an only one Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis Our demonstration of strong correlations between AUCs and plasma concentrations between four and eight hours after methotrexate intake suggests a simplified estimation of bioavailability and drug monitoring. Thus plasma sample analysis at a single time point could easily be used in daily practice. Further studies will be needed to establish relationships between dose and plasma concentrations as well as plasma concentrations and clinical effect.
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